NDA 216158 · Bristol-Myers
Cobenfy
Trospium Chloride, Xanomeline Tartrate · Oral · Cholinergic Muscarinic Agonist
NovelCDER novel approval, Sep 26, 2024: To treat schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Sep 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
64
26 Phase 3, 23 recruiting
FAERS reports
2,767
669 serious, 29 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 16, 2026.
COBENFY is indicated for the treatment of schizophrenia in adults. COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, indicated for the treatment of schizophrenia in adults. ( 1 )
Mechanism: The mechanism of action of xanomeline in the treatment of schizophrenia is unclear; however, its efficacy is thought to be due to its agonist activity at M1 and M4 muscarinic acetylcholine receptors in the central nervous system. Trospium chloride is a muscarinic antagonist. Trospium chloride antagonizes the muscarinic receptors primarily in the peripheral tissues.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- COBENFY · TROSPIUM CHLORIDE 30MG; XANOMELINE TARTRATE EQ 125MG BASE · CAPSULE, ORAL · Prescription
- COBENFY · TROSPIUM CHLORIDE 20MG; XANOMELINE TARTRATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
- COBENFY · TROSPIUM CHLORIDE 20MG; XANOMELINE TARTRATE EQ 100MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trospium Chloride" as an intervention, any sponsor and status, largest first.
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Pivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT05980949 · 1,000 participants (planned) · Start Jul 11, 2023 · Primary completion Sep 7, 2027
Drug: KarXT · For: Psychosis Associated With Alzheimer's Disease
Sites: Homewood, Alabama; Chandler, Arizona; Gilbert, Arizona · 432 sites in all
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06937229 · 650 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 22, 2029
Drug: KarXT; KarX-EC · For: Alzheimer Disease; Agitation
Sites: Chandler, Arizona; Scottsdale, Arizona; Anaheim, California · 255 sites in all
- InSite for Over Active BladderPivotal-lookingCompleted
MedtronicNeuroIndustry
NCT00547378 · 571 participants · Start Oct 2007 · Primary completion Aug 2016
Drug: Standard Medical Therapy · For: Urinary Incontinence, Urgency-frequency; Overactive Bladder
- An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)Pivotal-lookingCompleted
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT04820309 · 566 participants · Start Jun 2, 2021 · Primary completion May 24, 2024
Drug: Xanomeline and Trospium Chloride Capsules · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Anaheim, California · 117 sites in all
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Pivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT06126224 · 500 participants (planned) · Start Aug 28, 2023 · Primary completion Dec 9, 2026
Drug: KarXT; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Anaheim, California · 157 sites in all
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07686263 · 472 participants (planned) · Start Aug 20, 2026 · Primary completion Mar 3, 2029
Drug: Xanomeline/Trospium Chloride; Placebo · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 54 sites in all
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06929273 · 450 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 13, 2028
Drug: KarXT; Lithium and 2 more · For: Bipolar Disorder Type I With Mania
Sites: Glendale, Arizona; Scottsdale, Arizona; Tucson, Arizona · 191 sites in all
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07011732 · 426 participants (planned) · Start Jul 10, 2025 · Primary completion Nov 24, 2028
Drug: Xanomeline/Trospium Chloride Capsule; Xanomeline Enteric Capsule and 1 more · For: Alzheimer Disease
Sites: Scottsdale, Arizona; Anaheim, California; Fresno, California · 162 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea593
- vomiting439
- constipation202
- off label use195
- urinary retention153
- dizziness127
- dyspepsia112
- hyperhidrosis97
- vision blurred92
- drug ineffective84
- dry mouth82
- heart rate increased65
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 172 |
| 2025 | 1,254 |
| 2026 | 1,341 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cobenfy (Xanomeline Tart/Trospium Chlor)
2024 spending
$2.4M
Beneficiaries
961
1,539 claims
Per beneficiary
$2,455
$31.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,359,550 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
Kaul I, Sawchak S, Walling DP, et al. · JAMA Psychiatry 2024 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I, Sawchak S, Correll CU, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis.
Fabiano N, Wong S, Zhou C, et al. · Eur Neuropsychopharmacol 2025 · Systematic Review, Meta-Analysis
- Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
Kaul I, Claxton A, Chaturvedi S, et al. · Schizophr Res 2026 · Multicenter Study, Randomized Controlled Trial
- Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily.
Fröhlich G, Bulitta M, Strösser W · Int J Clin Pharmacol Ther 2002 · Meta-Analysis
- The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.
Horan WP, Sauder C, Harvey PD, et al. · Am J Psychiatry 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.